ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / COAG / news
MESO (51) VIR (40) REPL (50) VCEL (58) ⌘ Pro Terminal →

Why COAG Stock slipped -0.65% Today — RQD Quant Desk Flash

$41.18 -0.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $41.05

Hemab Therapeutics Holdings Inc. (COAG) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $1.92B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on COAG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is COAG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Hemab Therapeutics Holdings Inc. (NASDAQ: COAG) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $41.18 (-0.65% 1D, market cap $1.92B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, COAG ranks #168 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does COAG compare to MESO and VIR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), COAG carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MESO (Mesoblast Limited) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $1.89B) and VIR (Vir Biotechnology Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.88B). Among the 5-stock peer group, VCEL leads on earnings multiple (133.0x) while VCEL leads on capital efficiency (3.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for COAG?
▼

Per COAG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002114044), Hemab Therapeutics Holdings Inc. generated $81.8M in revenue, $0 in net income, and $0 in free cash flow against $194.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $41.05 (-0.31%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 65.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510059
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ · Rk C
Cash (10)Whales (15)SEC (13)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
$58 Bull$41 Base$32 Bear
📬 FREE COAG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COAG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY COAG SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$29.94+18% Next Q
Q2 (-2Q)
54
Grade C-$35.34+8.9% Next Q
Q3 (-1Q)
56
Grade C$38.50+7% Next Q
Current
59
Grade C-$41.18+0.2% Hist 90D α
Trajectory: C- (51) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the COAG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, COAG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($37.46) or 200D SMA ($36.88) invalidates the momentum regime and cuts Target Base ($41.37) toward Bear Floor ($32.27).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $COAG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “COAG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 59%NO 41%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why COAG Stock slipped -0.65% Today — RQD Quant Desk Flash

Hemab Therapeutics Holdings Inc. (COAG) slipped -0.65% to $41.18, trading at 56% of its 52-week range ($23 – $55.42). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

  • ▸Technical Tape: Trading at 56% of its 52-week range ($23 – $55.42) with RSI-14 at 64.3 (BULLISH MOMENTUM).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $41.18 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $53.9M annual free cash flow.
Live COAG Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (COAG Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
COAG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +64.72%⚡ TESTING RESISTANCE
2026-11-04O $41.45H $41.45L $41.18C $41.18VOL 343.9K
RES: $42.47SUP: $28.23SMA50: $37.46SMA200: $36.88
$57.69$48.29$38.89$29.48$20.08RES $42.47SUP $28.23$41.182026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

COAG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 COAG Butterfly Map → + Track COAG →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on COAG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for COAG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for COAG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COAG)

Health Care Rank #168 of 1015 ⚔️ MESO vs COAG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (COAG vs. MESO, VIR, REPL, VCEL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Hemab Therapeutics Holdings Inc. (COAG) ranks #168 by composite RQD confidence (59/100, grade C-) and #256 by equity capitalization ($1.92B). Within this direct 5-issuer industry benchmark cohort, VCEL leads on earnings valuation at 133.0x trailing P/E, while VCEL leads on capital efficiency and profitability with 3.4% ROIC and 74.4% gross margin. COAG currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
COAG ACTIVE
Hemab Therapeutics Holdings Inc.
C- 59/100 — — — -0.65% $1.92B Benchmark Subject
MESO
Mesoblast Limited
D 51/100 — — — -4.09% $1.89B /meso-vs-coag →
VIR
Vir Biotechnology Inc.
D- 40/100 — 96.0% -35.0% -2.65% $1.88B /vir-vs-coag →
REPL
Replimune Group Inc.
D 50/100 — — -35.0% +10.68% $1.85B /repl-vs-coag →
VCEL
Vericel Corporation
D+ 58/100 133.0x 74.4% 3.4% +0.62% $2.07B /vcel-vs-coag →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002114044 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hemab Therapeutics Holdings Inc. (COAG) reported GAAP revenue of $81.8M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, COAG closed FY2025 with $194.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $81.8M $0 — — $194.8M —

3. COAG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is COAG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Hemab Therapeutics Holdings Inc. (NASDAQ: COAG) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $41.18 (-0.65% 1D, market cap $1.92B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, COAG ranks #168 in composite RQD confidence.

How does COAG compare to MESO and VIR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), COAG carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MESO (Mesoblast Limited) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $1.89B) and VIR (Vir Biotechnology Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.88B). Among the 5-stock peer group, VCEL leads on earnings multiple (133.0x) while VCEL leads on capital efficiency (3.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for COAG?

Per COAG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002114044), Hemab Therapeutics Holdings Inc. generated $81.8M in revenue, $0 in net income, and $0 in free cash flow against $194.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is COAG trading relative to its 50-day, 200-day, and 52-week technical levels?

COAG last traded at $41.18 (-0.65% on volume of 343,889 shares), positioning the stock +9.93% above its 50-day simple moving average ($37.46) and +11.66% above its 200-day simple moving average ($36.88). Across its 52-week range of $23.00 to $55.42, COAG sits at the 56.1% percentile with a 14-day RSI of 64.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($36.03 to $46.33).

Direct Sub-Reports: COAG RQD Cockpit COAG 12M Forecast COAG Earnings & Move COAG Dividends & DRIP COAG Insiders & 13F COAG Whale Options COAG Profit Sankey COAG News & Why
ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

COAG — Hemab Therapeutics Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Hemab Therapeutics Holdings Inc. (COAG) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $41.18 (-0.65% 1D, market capitalization $1.92B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Hemab Therapeutics Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. It operates with a market capitalization of $1.9B. — for product lines, customers, or revenue model specifics.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Hemab Therapeutics Holdings Inc. (COAG) reported $81.8M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $194.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C- • RQD 59/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of — and institutional whale pillar of 15/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $23.00 – $55.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies, no links, and no proprietary signals. Sector-level correlations beyond the stated beta of 1.0 are not provided. The primary second-order watch item is the lock-up expiration on 28-OCT-2026, which could add supply to the market near the stated data date and may be a pressure point on trading dynamics.

  • Key Question #1: Can COAG sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $81.8M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is COAG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

COAG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Hemab Therapeutics Holdings Inc. (COAG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to COAG Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

COAG Bull vs. Bear Conversation Board — What's Your Call at $41.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON COAG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on COAG:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $53.47 (+29.0%)
📌 Pinned Debate

A JPMorgan Overweight initiation with a $70 price target, per the news wire, points to analyst support well above the current $40.42 pr

The street is overcomplicating Hemab Therapeutics Holdings Inc. (COAG). A JPMorgan Overweight initiation with a $70 price target, per the news wire, points to analyst support well above the current $40.42 price.. With an RQD score of 59/100 (C-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $44.77.

RetailWhale_TX 🐂 BULL

Both sides have a point here — COAG's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $35.65 (-14.0%)
Spot @ $41.45

With ROIC at 0% and FCF yield at 0% per the RQD rating, the $1.89B market cap rests on no current cash generation.

Careful chasing COAG at $41.45. With ROIC at 0% and FCF yield at 0% per the RQD rating, the $1.89B market cap rests on no current cash generation.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $35.65 on multiple compression.

LIVE TAPE